{'fraction_non_alphanumeric': 0.026041666666666668, 'fraction_numerical': 0.0, 'mean_word_length': 5.572649572649572, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Health advisory: high blood sugar and diabetes seen in protease inhibitor users.


 The Food and Drug Administration (FDA) has warned physicians that protease inhibitors may contribute to increased blood sugar or diabetes in HIV-positive patients, and recommends closely monitoring their glucose levels. These events occur relatively infrequently, and the FDA believes that the benefits of these drugs outweigh potential complications. All four approved protease inhibitors (saquinavir, indinavir, ritonavir, and nelfinavir) will soon carry revised labeling warning of this potential side effect. Patients taking protease inhibitors should be made aware of the warning signs of hyperglycemia and diabetes. The FDA's warning letter, detailing the effects, is included.
